accession,pubMedIds,platform_title,citation,name,platform_shorttitle,platform_summary,platform_manufacturer,platform_distribution,platform_accession,technology_type,year,title,warnings
GSE11237,18653328,Affymetrix Human Genome U95 Version 2 Array,"Auman JT, Church R, Lee SY, Watson MA, Fleshman JW, Mcleod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 2008 Aug","Auman, Mcleod 2008",Affymetrix HG_U95Av2,hg_u95av2,Affymetrix,commercial,GPL8300,in situ oligonucleotide,2008,Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation.,
GSE12225-GPL3676,18959792,NKI-CMF Homo sapiens 35k oligo array,"Lips EH, van Eijk R, de Graaf EJ, Oosting J et al. Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis.BMC Cancer 2008 Oct 29","Lips,  Morreau 2008",NA,nki-cmf homo sapiens 35k oligo array,NA,non-commercial,GPL3676,spotted oligonucleotide,2008,Integrating chromosomal aberrations and gene expression profiles to dissect rectal tumorigenesis.,
GSE12945,19399471,[HG-U133A] Affymetrix Human Genome U133A Array,"Staub E, Groene J, Heinze M, Mennerich D et al. An expression module of WIPF1-coexpressed genes identifies patients with favorable prognosis in three tumor types. J Mol Med (Berl) 2009 Jun","Staub, Rosenthal 2009",Affymetrix HG-U133A,hg-u133a,Affymetrix,commercial,GPL96,in situ oligonucleotide,2009,Expression data from colorectal cancers,
GSE13067,19088021,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Jorissen RN, Lipton L, Gibbs P, Chapman M et al. DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clin Cancer Res 2008 Dec 15",Jorissen and Sieber 2008,Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2008,Expression data from primary colorectal cancers,
GSE13294,19088021,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Jorissen RN, Lipton L, Gibbs P, Chapman M et al. DNA copy-number alterations underlie gene expression differences between microsatellite stable and unstable colorectal cancers. Clin Cancer Res 2008 Dec 15",Jorissen and Sieber 2008,Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2008,Expression data from primary colorectal cancers,
GSE14095,21680303,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Watanabe T, Kobunai T, Yamamoto Y, Matsuda K et al. Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. Clin Transl Oncol 2011 Jun","Watanabe, Hashimoto 2008",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2008,Gene expression signature and the prediction of liver metastasis in colorectal cancer by DNA microarray,
GSE14333,19996206,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Jorissen RN, Gibbs P, Christie M, Prakash S et al. Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clin Cancer Res 2009 Dec 15",Jorissen and Sieber 2008,Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2009,Expression data from 290 primary colorectal cancers,
GSE16125-GPL5175,19672874,[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version],"Reid JF, Gariboldi M, Sokolova V, Capobianco P et al. Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer 2009 Nov","Reid, Pierotti 2009",Affymetrix HuEx-1_0-st,huex-1_0-st,Affymetrix,commercial,GPL5175,in situ oligonucleotide,2009,Integrative approach for prioritizing cancer genes in sporadic colon cancer,
GSE17536,19914252,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Smith JJ, Deane NG, Wu F, Merchant NB et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010 Mar","Smith JJ, Beauchamp RD 2009",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2009,Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (Moffitt Samples),
GSE17537,19914252,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Smith JJ, Deane NG, Wu F, Merchant NB et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010 Mar","Smith JJ, Beauchamp RD 2009",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2009,Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients (VMC Samples),
GSE17538-GPL570,19914252,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Smith JJ, Deane NG, Wu F, Merchant NB et al. Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology 2010 Mar","Smith JJ, Beauchamp RD 2009",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2009,Experimentally Derived Metastasis Gene Expression Profile Predicts Recurrence and Death in Colon Cancer Patients,
GSE18105,20162577,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Matsuyama T, Ishikawa T, Mogushi K, Yoshida T et al. MUC12 mRNA expression is an independent marker of prognosis in stage II and stage III colorectal cancer. Int J Cancer 2010 Nov 15","Matsuyama, Sugihara 2009",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2009,Stage II and stage III colorectal cancer,
GSE2109,PMID unknown,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,NA,NA,Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2004,Expression Project for Oncology (expO),
GSE21510,21270110,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Tsukamoto S, Ishikawa T, Iida S, Ishiguro M et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res2011 Apr 15","Tsukamoto, Sugihara 2010",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2010,Clinical Significance of Osteoprotegerin Expression in Human Colorectal Cancer,
GSE21815,21862635,Agilent-014850 Whole Human Genome Microarray 4x44K G4112F (Probe Name version),"Kogo R, Shimamura T, Mimori K, Kawahara K et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res 2011 Oct 15","Mori M, Mimori K, Yokobori T 2010",Agilent G4112F,agilent-014850 whole human genome microarray 4x44k g4112f,Agilent,commercial,GPL6480,in situ oligonucleotide,2010,Gene expression profiles in 132 laser microdissected colorectal cancer tissues,
GSE24549-GPL5175,21619627,[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version],"Sveen A, Åesen TH, Rognum TO, Lothe RA, Skotheim RI. Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Med 2011 May 27","Sveen A, Åesen TH, Rognum TO, Lothe RA, Skotheim RI 2011",Affymetrix HuEx-1_0-st,huex-1_0-st,Affymetrix,commercial,GPL5175,in situ oligonucleotide,2010,Exon level expression profiling of colorectal cancer tissue samples (test sample series).,
GSE24550-GPL5175,21619627,[HuEx-1_0-st] Affymetrix Human Exon 1.0 ST Array [transcript (gene) version],"Sveen A, Agesen TH, Nesbakken A, Rognum TO et al. Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival.Genome Med 2011 May 27","Sveen A, Åesen TH, Rognum TO, Lothe RA, Skotheim RI 2011",Affymetrix HuEx-1_0-st,huex-1_0-st,Affymetrix,commercial,GPL5175,in situ oligonucleotide,2010,Exon level expression profiling of colorectal cancer tissue samples (validation sample series).,
GSE2630,17390049,Human 19K oligo array,"BandréE, Malumbres R, Cubedo E, Sola J, GarcíFoncillas J, Labarga A. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol Rep 2007 May","BandréE, Malumbres R, Cubedo E, Sola J, GarcíFoncillas J, Labarga A 2005",NA,human 19k oligo array,NA,non-commercial,GPL2006,spotted oligonucleotide,2005,Gene signature for relapse prediction in Dukes´B colon cancer,
GSE26682-GPL570,21300766,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Vilar E, Gruber SB, Rennert G, Bartnik CM, Stenzel SL, Iniesta MD, Raskin L,Mukherjee B, Ahn J, Moreno V, Morgan MA. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011 Apr 1","Vilar E, Morgan MA 2011",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2011,MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers.,
GSE26682-GPL96,21300766,[HG-U133A] Affymetrix Human Genome U133A Array,"Vilar E, Gruber SB, Rennert G, Bartnik CM, Stenzel SL, Iniesta MD, Raskin L,Mukherjee B, Ahn J, Moreno V, Morgan MA. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011 Apr 1","Vilar E, Morgan MA 2011",Affymetrix HG-U133A,hg-u133a,Affymetrix,commercial,GPL96,in situ oligonucleotide,2011,MRE11 Deficiency Increases Sensitivity to Poly(ADP-ribose) Polymerase Inhibition in Microsatellite Unstable Colorectal Cancers.,
GSE26906,22496922,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Birnbaum DJ, Laibe S, Ferrari A, Lagarde A et al. Expression Profiles in Stage II Colon Cancer According to APC Gene Status. Transl Oncol 2012 Apr",Olschwang S 2011,Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2011,Genomic aberrations in distant fields from oral potentially malignant lesions by high resolution DNA flow cytometry and array-CGH,
GSE27544,PMID unknown,[HT_HG-U133_Plus_PM] Affymetrix HT HG-U133+ PM Array Plate,NA,"Bernal M, GarcíAlcalde F, Concha Á Blanco A, Garrido F, Ruiz-Cabello F 2011",Affymetrix HT HG-U133+ PM,ht_hg-u133_plus_pm,Affymetrix,commercial,GPL13158,in situ oligonucleotide,2011,Genome-wide profiling characterizes CRCs with genetic instability and specific routes to HLA class I loss and immunoescape,
GSE28702,22095227,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Tsuji S, Midorikawa Y, Takahashi T, Yagi K et al. Potential responders to FOLFOX therapy for colorectal cancer by Random Forests analysis. Br J Cancer 2012 Jan 3",Tsuji 2011,Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2011,CRC samples for FOLFOX therapy prediction,
GSE3294,16773188,UHN SS-Human 19Kv7,"Bianchini M, Levy E, Zucchini C, Pinski V et al. Comparative study of gene expression by cDNA microarray in human colorectal cancer tissues and normal mucosa. Int J Oncol 2006 Jul",Bianchini 2005,UHN SS-Human 19Kv7,uhn ss-human 19kv7,UHN,commercial,GPL2829,spotted DNA/cDNA,2005,Comparative study of gene expression in human colorectal cancer tissues and normal mucosa,
GSE33113,22496204,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"de Sousa E Melo F, Colak S, Buikhuisen J, Koster J et al. Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients. Cell Stem Cell 2011 Nov 4","Medema JP, Tanis PJ 2011",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2011,AMC colon cancer AJCCII,
GSE39582,23700391,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Marisa L, de ReynièA, Duval A, Selves J et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013","Marisa, Boige 2012",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2012,"Gene expression Classification of Colon Cancer defines six molecular subtypes with distinct clinical, molecular and survival characteristics [Expression]",
GSE3964,16542501,11K_VJF-ARRAY,"Graudens E, Boulanger V, Mollard C, Mariage-Samson R et al. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006","Graudens, Imbeaud 2006",NA,11k_vjf-array,NA,non-commercial,GPL3282,spotted DNA/cDNA,2006,Deciphering cellular states of innate tumor drug responses,
GSE4045,16819509,[HG-U133A] Affymetrix Human Genome U133A Array,"Laiho P, Kokko A, Vanharanta S, Salovaara R et al. Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene2007 Jan 11","Laiho, Aaltonen 2007",Affymetrix HG-U133A,hg-u133a,Affymetrix,commercial,GPL96,in situ oligonucleotide,2006,Classification of serrated colorectal tumors,
GSE4526,19016304,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,"Watanabe T, Kobunai T, Sakamoto E, Yamamoto Y et al. Gene expression signature for recurrence in stage III colorectal cancers. Cancer 2009 Jan 15","Watanabe T, Kobunai T, Toda E, Oka T 2006",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2006,Gene expression signature and the prediction of recurrence in stage III colorectal cancer by DNA microarray,
GSE45270,PMID unknown,[HG-U133_Plus_2] Affymetrix Human Genome U133 Plus 2.0 Array,,"Medema JP, de Sousa E Melo F, Vermeulen L, Jansen M, Dekker E, Van Noesel C, Fessler E 2013",Affymetrix HG-U133Plus2,hg-u133_plus_2,Affymetrix,commercial,GPL570,in situ oligonucleotide,2013,AMC tubular and serrated adenomas,
TCGA-COAD,22810696,Agilent 244K Custom Gene Expression G4502A-07-3,"Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337",The Cancer Genome Atlas Network 2012,Agilent G4502A-07-3,agilent-014850 whole human genome microarray 4x44k g4112f,Agilent,commercial,NA,in situ oligonucleotide,2012,Comprehensive molecular characterization of human colon and rectal cancer.,
TCGA-RNASeqV2,22810696,[RNASeqV2] Illumina HiSeq RNA sequencing,"Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337",The Cancer Genome Atlas Network 2012,,NA,Illumina,sequencing,NA,in situ oligonucleotide,2012,Comprehensive molecular characterization of human colon and rectal cancer.,
TCGA-READ,22810696,Agilent 244K Custom Gene Expression G4502A-07-3,"Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337",The Cancer Genome Atlas Network 2012,Agilent G4502A-07-3,agilent-014850 whole human genome microarray 4x44k g4112f,Agilent,commercial,NA,in situ oligonucleotide,2012,Comprehensive molecular characterization of human colon and rectal cancer.,
TCGA-RNASeqV2-READ,22810696,[RNASeqV2] Illumina HiSeq RNA sequencing,"Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337",The Cancer Genome Atlas Network 2012,,NA,Illumina,sequencing,NA,in situ oligonucleotide,2012,Comprehensive molecular characterization of human colon and rectal cancer.,

